Abel Hall LLC Takes $33,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

Abel Hall LLC bought a new stake in Century Therapeutics, Inc. (NASDAQ:IPSC) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 10,071 shares of the company’s stock, valued at approximately $33,000.

Separately, Avidity Partners Management LP lifted its position in Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after acquiring an additional 256,500 shares in the last quarter. Institutional investors own 50.20% of the company’s stock.

Wall Street Analysts Forecast Growth

IPSC has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price target (down previously from $10.00) on shares of Century Therapeutics in a research report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Century Therapeutics in a research report on Tuesday, June 4th. Finally, Canaccord Genuity Group raised their price target on shares of Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, March 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Century Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $13.20.

Century Therapeutics Price Performance

Shares of NASDAQ IPSC traded down $0.13 during midday trading on Friday, reaching $3.13. The company’s stock had a trading volume of 110,931 shares, compared to its average volume of 121,281. Century Therapeutics, Inc. has a 12-month low of $1.28 and a 12-month high of $5.51. The firm has a 50 day moving average price of $3.18 and a 200-day moving average price of $3.53.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. Century Therapeutics had a negative return on equity of 59.74% and a negative net margin of 9,742.41%. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.30 million. On average, equities analysts anticipate that Century Therapeutics, Inc. will post -1.94 EPS for the current year.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.